<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04501978</url>
  </required_header>
  <id_info>
    <org_study_id>014 / ACTIV-3</org_study_id>
    <nct_id>NCT04501978</nct_id>
  </id_info>
  <brief_title>ACTIV-3: Therapeutics for Inpatients With COVID-19</brief_title>
  <acronym>TICO</acronym>
  <official_title>A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kirby Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington D.C. Veterans Affairs Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>AIDS Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>US Department of Veterans Affairs</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Prevention and Early Treatment of Acute Lung Injury (PETAL)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cardiothoracic Surgical Trials Network (CTSN)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vir Biotechnology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brii Biosciences Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Molecular Partners AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study looks at the safety and effectiveness of different drugs in treating COVID-19 in&#xD;
      people who have been hospitalized with the infection. Participants in the study will be&#xD;
      treated with either a study drug plus current standard of care (SOC), or with placebo plus&#xD;
      current SOC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a master protocol to evaluate the safety and efficacy of multiple investigational&#xD;
      agents aimed at modifying the host immune response to SARS-CoV-2 infection, or directly&#xD;
      enhancing viral control in order to limit disease progression.&#xD;
&#xD;
      The protocol is for a randomized, blinded, controlled platform study that allows&#xD;
      investigational drugs to be added and dropped during the course of the study. This allows for&#xD;
      efficient testing of new drugs against placebo and standard of care (SOC) treatment within&#xD;
      the same study. When more than one drug is being tested at the same time, participants will&#xD;
      be randomly allocated to treatments or placebo.&#xD;
&#xD;
      Randomization will be stratified by study site pharmacy and disease severity. There are 2&#xD;
      disease severity strata: Participants without organ failure (severity stratum 1); and&#xD;
      participants with organ failure (severity stratum 2).&#xD;
&#xD;
      An independent Data and Safety Monitoring Board (DSMB) will regularly review interim analyses&#xD;
      and summarize safety and efficacy outcomes. For investigational drugs with minimal&#xD;
      pre-existing safety knowledge, the pace of enrollment with be initially restricted, and there&#xD;
      will be an early review of safety data by the DSMB. For the study of each agent, at the&#xD;
      outset of the trial, only participants in disease severity stratum 1 will be enrolled. This&#xD;
      will continue until approximately 300 participants are enrolled and followed for 5 days. The&#xD;
      exact number will vary according to the speed of enrollment and the timing of DSMB meetings.&#xD;
      Prior to expanding enrollment to also include patients in disease severity stratum 2, safety&#xD;
      will be evaluated and a pre-specified futility assessment by the DSMB will be carried out&#xD;
      using 2 ordinal outcomes assessed at Day 5.&#xD;
&#xD;
      Both ordinal outcomes are used to assess futility because it is currently unclear whether the&#xD;
      investigational agents under study will primarily influence non-pulmonary outcomes, for which&#xD;
      risk is increased with SARS-CoV-2 infection, in part, through mechanisms that may be&#xD;
      different from those that influence pulmonary outcomes.&#xD;
&#xD;
      For investigational agents passing this futility assessment, enrollment of participants will&#xD;
      be expanded, seamlessly and without any data unblinding, to include participants in disease&#xD;
      severity stratum 2 as well as those in disease severity stratum 1. Future interim analyses&#xD;
      will be based on the primary endpoint of sustained recovery and will use pre-specified&#xD;
      guidelines to determine early evidence of benefit, harm or futility for the investigational&#xD;
      agent. Participants will be followed for 18 months following randomization.&#xD;
&#xD;
      The international trials within this protocol will be conducted in several hundred clinical&#xD;
      sites. Participating sites are affiliated with networks funded by the United States National&#xD;
      Institutes of Health (NIH) and the US Department of Veterans Affairs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 4, 2020</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time from randomization to sustained recovery</measure>
    <time_frame>Up to Day 90</time_frame>
    <description>Sustained recovery defined as being discharged from the index hospitalization, followed by being alive and home for 14 consecutive days prior to Day 90.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Thru Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of time to sustained recovery and mortality</measure>
    <time_frame>Thru Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive outside short-term acute care hospital</measure>
    <time_frame>Up to Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary ordinal outcome</measure>
    <time_frame>Days 1-7, 14 and 28</time_frame>
    <description>Oxygen requirements measured by 7 categories (1 = least severe, 7 = most severe). The participant's highest (i.e. most severe) observed score is used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary+ ordinal outcome</measure>
    <time_frame>Days 1-7</time_frame>
    <description>Extrapulmonary complications and respiratory dysfunction measured by 7 categories (1= least severe, 7 = most severe). The participant's highest (i.e. most severe) observed score is used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinical organ failure</measure>
    <time_frame>Thru Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of death or serious clinical COVID-19 related events</measure>
    <time_frame>Thru Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of cardiovascular events and thromboembolic events</measure>
    <time_frame>Thru Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of grade 3 and 4 clinical adverse events, serious adverse events (SAEs) or death</measure>
    <time_frame>Thru Days 5 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infusion reactions</measure>
    <time_frame>Thru Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of SAEs or death</measure>
    <time_frame>Thru 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SARS-CoV-2 neutralizing antibody levels</measure>
    <time_frame>Baseline to Days 1, 3, 5, 28 and 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in overall titers of antibodies</measure>
    <time_frame>Baseline to Days 1, 3, 5, 28 and 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in neutralizing antibody levels</measure>
    <time_frame>Baseline to Days 1, 3, 5, 28 and 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of home use of supplemental oxygen above pre-morbid oxygen use</measure>
    <time_frame>18 months</time_frame>
    <description>Measured as: Alive at home and no use of continuous supplemental oxygen for an uninterrupted 14 day period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of no home use of supplemental oxygen above pre-morbid oxygen use</measure>
    <time_frame>14 days</time_frame>
    <description>Measured as: Alive at home for an uninterrupted 14 day period and no use of continuous supplemental oxygen at end of 14 day time period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>ACTIV-3 Drug plus SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this study will be randomized to receive one of the ACTIV-3 drug treatments plus Standard of Care (SOC) or placebo plus SOC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo plus SOC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo arm may be pooled across more than one experimental arm if multiple investigational drugs are available to be tested at the same time. If it is not possible to use matching placebo over more than one experimental arm, additional placebo arms will be included in the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LY3819253</intervention_name>
    <description>Participants are no longer being randomized to this intervention.</description>
    <arm_group_label>ACTIV-3 Drug plus SOC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Commercially available 0.9% sodium chloride solution. Administered by IV infusion</description>
    <arm_group_label>Placebo plus SOC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Remdesivir</intervention_name>
    <description>Provided to all study participants as SOC unless contraindicated for an individual patient.</description>
    <arm_group_label>ACTIV-3 Drug plus SOC</arm_group_label>
    <arm_group_label>Placebo plus SOC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VIR-7831</intervention_name>
    <description>Participants are no longer being randomized to this intervention.</description>
    <arm_group_label>ACTIV-3 Drug plus SOC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BRII-196/BRII-198</intervention_name>
    <description>Participants are no longer being randomized to this intervention.</description>
    <arm_group_label>ACTIV-3 Drug plus SOC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AZD7442</intervention_name>
    <description>Participants are no longer being randomized to this intervention.</description>
    <arm_group_label>ACTIV-3 Drug plus SOC</arm_group_label>
    <other_name>AZD8895 + AZD1061</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MP0420</intervention_name>
    <description>600 mg. Administered by IV infusion as a single dose</description>
    <arm_group_label>ACTIV-3 Drug plus SOC</arm_group_label>
    <other_name>ensovibep</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-07304814</intervention_name>
    <description>250 mg per day for 5 days. Administered as a constant rate intravenous infusion</description>
    <arm_group_label>ACTIV-3 Drug plus SOC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
          -  Positive test for COVID-19 and progressive disease suggestive of ongoing COVID-19&#xD;
             infection.&#xD;
&#xD;
          -  Symptoms of COVID-19 for â‰¤ 12 days.&#xD;
&#xD;
          -  Require admission to hospital for acute medical care (not for purely public health or&#xD;
             quarantine purposes).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have received plasma from a person who recovered from COVID-19 or who&#xD;
             have received neutralizing monoclonal antibodies at any time prior to hospitalization.&#xD;
&#xD;
          -  Patients not willing to abstain from participation in other COVID-19 treatment trials&#xD;
             until after Day 5 of the study. Co-enrollment in certain trials that compare&#xD;
             recommended Standard of Care treatments may be allowed, based on the opinion of the&#xD;
             study leadership team.&#xD;
&#xD;
          -  Any condition which, in the opinion of the responsible investigator, participation&#xD;
             would not be in the best interest of the participant or that could prevent, limit, or&#xD;
             confound the protocol-specified assessments.&#xD;
&#xD;
          -  Patients considered unable to participate in study procedures.&#xD;
&#xD;
          -  Women of child-bearing potential who are not already pregnant at study entry and who&#xD;
             are unwilling to acknowledge strong advice to abstain from sexual intercourse with men&#xD;
             or practice appropriate contraception through 18 months of the study.&#xD;
&#xD;
          -  Women of child-bearing potential who are unwilling to acknowledge the strong advice to&#xD;
             abstain from sexual intercourse with men or practice appropriate contraception through&#xD;
             5 weeks of the study (PF-07304814 investigational agent).&#xD;
&#xD;
          -  Pregnant women (MP0420 and PF-07304814 investigational agents).&#xD;
&#xD;
          -  Nursing mothers (MP0420 and PF-07304814 investigational agents).&#xD;
&#xD;
          -  Men who are unwilling to acknowledge the strong advice to abstain from sexual&#xD;
             intercourse with women of child-bearing potential or to use barrier contraception&#xD;
             through 18 months of the study.&#xD;
&#xD;
          -  Men who are unwilling to acknowledge the strong advice to abstain from sexual&#xD;
             intercourse with women of child-bearing potential or to use barrier contraception&#xD;
             through 5 weeks of the study (PF-07304814 investigational agent).&#xD;
&#xD;
          -  Presence at study enrollment of any of the following:&#xD;
&#xD;
               1. stroke&#xD;
&#xD;
               2. meningitis&#xD;
&#xD;
               3. encephalitis&#xD;
&#xD;
               4. myelitis&#xD;
&#xD;
               5. myocardial ischemia&#xD;
&#xD;
               6. myocarditis&#xD;
&#xD;
               7. pericarditis&#xD;
&#xD;
               8. symptomatic congestive heart failure&#xD;
&#xD;
               9. arterial or deep venous thrombosis or pulmonary embolism&#xD;
&#xD;
          -  Current or imminent requirement for any of the following:&#xD;
&#xD;
               1. invasive mechanical ventilation&#xD;
&#xD;
               2. ECMO (extracorporeal membrane oxygenation)&#xD;
&#xD;
               3. Mechanical circulatory support&#xD;
&#xD;
               4. vasopressor therapy&#xD;
&#xD;
               5. commencement of renal replacement therapy at this admission (i.e. not patients on&#xD;
                  chronic renal replacement therapy).&#xD;
&#xD;
          -  Participants with moderate to severe hepatic impairment (i.e. Child-Pugh class B or C)&#xD;
             or acute liver failure (PF-07304814 investigational agent).&#xD;
&#xD;
          -  Participants receiving any medications or substances that are strong inhibitors or&#xD;
             inducers of cytochrome P450 (CYP) 3A4 (PF-07304814 investigational agent).&#xD;
&#xD;
          -  Patients will be excluded if taking drugs which have a narrow therapeutic window that&#xD;
             are substrates of CYP3A4, including but not limited to: astemizole, cisapride,&#xD;
             cyclosporine, dihydroergotamine, ergotamine, pimozide, quinidine, sirolimus,&#xD;
             tacrolimus, and terfenadine (PF-07304814 investigational agent).&#xD;
&#xD;
          -  Patients with a history of deep vein thrombosis or pulmonary thrombotic embolism&#xD;
             (Prior to initial futility assessment of PF-07304814 investigational agent).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Jens Lundgren</last_name>
    <role>Principal Investigator</role>
    <affiliation>INSIGHT Copenhagen International Coordinating Centre, Rigshospitalet, University of Copenhagen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prof. James Neaton</last_name>
    <role>Study Chair</role>
    <affiliation>INSIGHT Statistical and Coordinating Centre, University of Minnesota</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>If interested in participating in this study, please contact the appropriate site or</last_name>
    <phone>send email to</phone>
    <email>tico@insight-trials.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Do not include personal information in email. Type ACTIV-3 in subject line.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Banner University Medical Center Tucson (Site 206-004), 1625 N. Campbell Avenue</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Southern Arizona VA Healthcare System (Site 074-009), 3601 S. 6th Ave.</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85723</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email, and send to</last_name>
      <email>ticova@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Velocity Chula Vista (Site 080-034), 752 Medical Center Ct., Ste. 304</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticonih@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Community Regional Medical Center (Site 203-005), 2823 Fresno Street</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Velocity San Diego (Site 080-035), 5565 Grossmont Center Drive, Building 2, Suite 1</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticonih@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>VA Loma Linda Healthcare System (Site 074-017), 11201 Benton Street</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92357</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticova@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>VA Long Beach Healthcare System (Site 074-026), 5901 East 7th Street (09/151-M2)</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticova@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Keck Hospital of USC (Site 301-020), 1500 San Pablo Street</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticoctsn@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center (Site 208-002), 8700 Beverly Blvd.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ronald Reagan UCLA Medical Center (Site 203-002), 757 Westwood Plaza</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Sacramento VA Medical Center (Site 074-023), 10535 Hospital Way</name>
      <address>
        <city>Mather</city>
        <state>California</state>
        <zip>95655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticova@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hoag Memorial Hospital Presbyterian (Site 080-026), One Hoag Drive</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticonih@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Palo Alto Health Care System (Site 074-005), 3801 Miranda Avenue</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticova@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>UC Davis Health (Site 203-004), 2315 Stockton Blvd.</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>VA San Diego Healthcare System (Site 074-016), 3350 La Jolla Village Drive</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticova@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center at Mount Zion (Site 203-007), 1600 Divisadero St.</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>San Francisco VAMC (Site 074-002), 4150 Clement St.</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticova@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center (Site 203-001), Moffitt-Long Hospital, 505 Parnassus Ave.</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Stanford University Hospital &amp; Clinics (Site 203-003), 300 Pasteur Dr.</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (Site 066-002), 1124 W. Carson Street, CDCRC Building</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticowdc@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital (Site 204-001), 12605 E. 16th Avenue</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Denver Public Health (Site 017-004), 660 Bannock St., MC2600 (Infectious Disease Clinic)</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticowdc@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>National Jewish Health (Site 204-003), 1400 Jackson Street</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email, and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>West Haven VA Medical Center (Site 025-007), 950 Campbell Avenue</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticowdc@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>MedStar Georgetown University Hospital (Site 067-001), 3800 Reservoir Road NW</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>MedStar Health Research Institute (Site 009-021), MedStar Washington Hospital Center, 110 Irving St., NW.</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticowdc@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Washington DC VA Medical Center (Site 009-004), 50 Irving Street NW</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20422</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticowdc@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Bay Pines VAMC (Site 074-004), 10000 Bay Pines Blvd., Bldg. 100, Room 5B-104</name>
      <address>
        <city>Bay Pines</city>
        <state>Florida</state>
        <zip>33744</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticova@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Baycare Health System (Site 301-025), Morton Plant Hospital, 300 Pinellas Street</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticoctsn@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>North Florida/South Georgia Veterans Health System (Site 074-011), 1601 SW. Archer Road</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608-1197</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticova@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Memorial Healthcare System (Site 648-002), Memorial Regional Hospital, 3501 Johnson Street</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticonih@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Miami VA Healthcare System (Site 074-003), 1201 NW 16 Street</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACITV-3 in subject line of email and send to</last_name>
      <email>ticova@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hillsborough County Health Department, University of South Florida (Site 032-001)</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticowdc@insight-trials.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University (Site 301-008), The Emory Clinic, Bldg. A, Suite 2236, 1365 Clifton Rd., NE</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticoctsn@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Lutheran Medical Group (Site 301-010), 7916 W. Jefferson Boulevard</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticoctsn@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cotton O'Neil Clinical Research Center (Site 080-030), Stormont Vail Health, 1500 SW 10th Avenue</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticonih@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Hospital (Site 210-004), 1000 South Limestone St.</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation (Site 301-015), 1514 Jefferson Highway</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticoctsn@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center (Site 301-019), 22 South Greene Street</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticoctsn@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital (Site 202-002), 55 Fruit Street</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center (Site 202-001), 330 Brookline Ave.</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Baystate Medical Center (Site 201-001), 759 Chestnut Street</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Michigan (Site 205-001), 1500 East Medical Center Drive</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System, Henry Ford Hospital (Site 014-001), 2799 W. Grand Blvd.</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticowdc@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute Foundation (Site 301-026), Abbott Northwestern Hospital, 920 E 28th St. #100</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in partitipating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticoctsn@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hennepin Healthcare (Site 027-001), 701 Park Avenue</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticowdc@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Minneapolis VA Health Care System (Site 105-001), 1 Veterans Drive, Bldg 70</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticowdc@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>M Health Fairview University of Minnesota Medical Center (Site 112-001), 500 Harvard St. SE.</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticowdc@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center (Site 202-005), 2500 North State Street</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>VA St. Louis Healthcare System (Site 074-027), 915 North Grand Blvd., Rm. C201</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticova@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center/Mary Hitchcock Memorial Hospital (Site 301-024), One Medical Center Drive</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticoctsn@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cooper University Hospital (Site 019-001), One Cooper Plaza</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticowdc@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Lincoln Medical Center (New York Health and Hospitals/Lincoln) (Site 003-016), 234 E. 149th Street</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10451</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticonih@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center Weiler Hospital (Site 206-003), 1825 Eastchester Road</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center Moses Hospital (Site 206-001), 111 E. 210th Street</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>SUNY Downstate Medical Center (Site 033-001), 450 Clarkson Ave.</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticowdc@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Maimonides Medical Center (Site 033-002), 4802 10th Avenue</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticonih@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Duke University Hospital (Site 301-006), 2301 Erwin Road</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticoctsn@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences (Site 210-001), Medical Center Blvd</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center (Site 207-003), 234 Goodman Ave.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center (Site 108-001), 11100 Euclid Avenue</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticowdc@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Fairview Hospital (Site 207-005), 18101 Lorain Avenue</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation (Site 207-001), 9500 Euclid Avenue</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Marymount Hospital (Site 207-006), 12300 McCraken Road</name>
      <address>
        <city>Garfield Heights</city>
        <state>Ohio</state>
        <zip>44125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University (Site 208-003), 3181 SW Sam Jackson Park Rd.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Portland VA Healthcare System (Site 074-024), 3710 SW. US Veterans Hospital Road</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticova@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>UPMC Magee-Womens Hospital (Site 209-003), 300 Halket Street</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>UPMC Presbyterian Hospital (Site 209-001), 200 Lothrop Street</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal informaiton in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>UPMC Shadyside Hospital (Site 209-005), 5230 Centre Avenue</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital (Site 080-036), 593 Eddy Street</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticonih@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Miriam Hospital (Site 080-039), 164 Summit Ave.</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticonih@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>VA Providence Healthcare System (Site 074-025), 830 Chalkstone Ave.</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticova@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ralph H. Johnson VA Medical Center (Site 074-015), 109 Bee Street</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticova@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>MUSC Research Nexus Clinic (Site 210-002), 96 Jonathan Lucas St., CSB 214</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>MUSC Health Florence Medical Center (Site 210-006), 805 Pamplico Highway</name>
      <address>
        <city>Florence</city>
        <state>South Carolina</state>
        <zip>29505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>VA TVHS Nashville Campus (Site 074-022), 1310 24th Avenue South</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticova@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center (Site 212-001), 1211 Medical Center Drive</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hendrick Medical Center (Site 080-014), 1900 Pine Street</name>
      <address>
        <city>Abilene</city>
        <state>Texas</state>
        <zip>79601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticonih@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHRISTUS Spohn Shoreline Hospital (Site 080-001), 600 Elizabeth Street</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticonih@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Parkland Health and Hospital Systems (Site 084-002), 5200 Harry Hines Blvd</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticowdc@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center (Site 084-001), 1936 Amelia Court, 2nd Floor</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticowdc@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Baylor, Scott and White Health (Site 301-003), Baylor University Medical Center, 3500 Gaston Ave.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticoctsn@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Memorial Hermann Hospital (Site 203-006), 6411 Fannin Street</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Michael E. DeBakey Veterans Affairs Medical Center (MEDV AMC) (Site 074-006), 2002 Holcombe Blvd.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticowdc@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Texas Heart Institute (Site 301-017), 6770 Bertner, MC4-266</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticoctsn@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHRISTUS Good Shepherd Medical Center (Site 080-031), 700 E. Marshall Ave.</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticonih@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center (Site 211-001), 5121 South Cottonwood Street</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Utah Health (Site 211-002), 419 Wakara Way, Suite 207</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>LDS Hospital (Site 211-004), 8th Ave. C Street</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health Systems (Site 301-021), 1215 Lee Street</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticoctsn@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Health System (Site 210-005), 1250 East Marshall Street</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carilion Clinic (Site 080-018), 2001 Crystal Springs Ave., Suite 301</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticonih@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Salem VA Medical Center (Site 074-014), 1970 Roanoke Blvd.</name>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <zip>24153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticova@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Harborview Medical Center (Site 208-001), 325 9th Avenue</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Hospital First Hill (Site 208-005), 747 Broadway</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center - Montlake (Site 208-006), 1959 NE Pacific Street</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>West Virginia University (Site 301-023), One Medical Center Drive</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticoctsn@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital General de Agudos Dr. JM Ramos Mejia (Site 611-001), Urquiza 609</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aire</city>
        <zip>C1221ADC</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticosyd@insight-trials.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aalborg Hospital (Site 625-005), Hobrovej 18</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticocph@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Aarhus Universitetshospital, Skejby (Site 625-002), Department of Infectious Diseases, Palle Juul-Hensens Boulevard 99</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticocph@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Righospitalet (Site 625-006), Blegdamsvej 9,</name>
      <address>
        <city>Copenhagen Ã˜</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticocph@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Bispebjerg Hospital (Site 625-013), Bispebjerg Bakke 23</name>
      <address>
        <city>Copenhagen</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticocph@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Herlev/Gentofte Hospital (Site 625-012), Medicinsk Afdeling,Gentofte Hosptialsvej 7, Studen</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticocph@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>NordsjÃ¦llands Hospital (Site 625-009), Dyrehavevej 29</name>
      <address>
        <city>HillerÃ¸d</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticocph@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hvidovre University Hospital, Department of Infectious Diseases (Site 625-001), KettegÃ¥rd allÃ© 30</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticocph@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Kolding Sygehus (Site 625-011), Medicinsk Afdeling, Sygehusvej 24</name>
      <address>
        <city>Kolding</city>
        <zip>6000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticocph@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital (Site 625-004), Infektionsmedicinsk Forskningsenhed,J.B. WinslÃ¸wsgade 4</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticocph@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Zealand University Hospital, Roskilde (Site 625-010), Sygehusvej 10</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If intersted in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticocph@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>AIDS and Clinical Immunology Research Center (Site 627-201), Infectious Diseases, 16 Al. Kazbegi Avenue</name>
      <address>
        <city>Tbilisi</city>
        <zip>0160</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticocph@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Democritus University of Thrace (Site 635-021), University General Hospital of Alexandroupolis, Dragana</name>
      <address>
        <city>Alexandroupolis</city>
        <state>Evros</state>
        <zip>68131</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticolon@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Evangelismos COVID-19 Unit, (Site 635-020), 1st Dept. of Pulmonary and Critical Care Medicine, Evangelismos General Hospital, Dept., Ipsilantou 45-47</name>
      <address>
        <city>Athens</city>
        <zip>106 76</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticolon@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>1st Respiratory Medicine Dept., Athens University Medical School (Site 635-015), Athens Hospital for Diseases of the Chest &quot;Sotiria Hospital&quot;, 152 Mesogeion Ave.</name>
      <address>
        <city>Athens</city>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticolon@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>3rd Dept. of Medicine, Medical School, NKUA (Site 635-022), Sotiria General Hospital, 152 Mesogeion Ave.</name>
      <address>
        <city>Athens</city>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticolon@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Attikon University General Hospital (Site 635-009), 4th Dept. of Internal Medicine, Medical School, National and Kapodistrian University of Athens, 1 Rimini St., Haidari</name>
      <address>
        <city>Athens</city>
        <zip>124 62</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticolon@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Chennai Antiviral Research and Treatment Clinical Research Site (Site 612-402), VHS-IDMC, Voluntary Health Services, Rajiv Gandhi Salai, Taramani</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600113</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticosyd@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Medical Centre, Voluntary Health Services (Site 612-402), Rajiv Gandhi Salai, Taramani</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600113</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticosyd@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centro de InvestigaÃ§Ã£o e Treino em SaÃºde da Polana CaniÃ§o (CISPOC) (Site 634-701), Instituto Nacional de SaÃºde (INS), Rua da Costa do Sol, 178, Polana CaniÃ§o B</name>
      <address>
        <city>Maputo</city>
        <country>Mozambique</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticolon@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Institute of Human Virology Nigeria (IHVN) (Site 612-601), Plot 252, Herbert Macaulay Way, Central Business District</name>
      <address>
        <city>Abuja</city>
        <country>Nigeria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticosyd@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>WojewÃ³dzki Szpital Zakazny (Site 625-302), Wolska 37</name>
      <address>
        <city>Warsaw</city>
        <zip>01-201</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticocph@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Tan Tock Seng Hospital (Site 612-201), National Centre for Infectious Diseases (NCID), 11 Jalan Tan Tock Seng</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticosyd@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Germans Trias i Pujol Hospital (Site 626-003), Infectious Disease Unit, Second Floor, Building Maternal, Road Canyet s/n</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticocph@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Arnau de Vilanova (Site 626-035), Av. Alcalde Rovira Roure 80</name>
      <address>
        <city>Lleida</city>
        <state>Leida</state>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticocph@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Del Mar (Site 626-025), Paseo Maritimo 25-29</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticocph@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron (Site 626-033), Passeig de la Vall d'Hebron 119-129</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticocph@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital ClÃ­nic de Barcelona (Site 626-004), Carrer de Villaroel 170</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticocph@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Bellvitge (Site 626-034), Carrer de la Feixa Llarga, s/n</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticocph@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio MaraÃ±Ã³n (Site 626-001), Dr. Esquerdo, 46</name>
      <address>
        <city>Madrid</city>
        <zip>28017</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticocph@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital ClÃ­nico San Carlos (Site 626-017), Enfermedades infecciosas, C/Martin Lagos CN</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticocph@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>UCICEC (Clinical Trial Unit) Hospital Universitario La Paz (Site 626-012), Paseo de la Castellana 261, 2a planta Hospital Maternal</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticocph@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital Zurich (Site 621-201), Department of Infectious Diseases and Hospital Epidemiology, Raemistrasse 100</name>
      <address>
        <city>ZÃ¼rich</city>
        <state>Zurich</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticocph@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>MRC/UVRI and LSHTM Uganda Research Unit (Site 634-601), Entebbe Regional Referral Hospital</name>
      <address>
        <city>Entebbe</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticolon@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Gulu Regional Referral Hospital (Site 634-603), Laroo Division, PO Box 160</name>
      <address>
        <city>Gulu</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticolon@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Makerere University Lung Institute (Site 634-604), New Mulago Hospital Complex, Mulago Hill</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticolon@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>St. Francis Hospital, Nsambya (Site 634-607), Nsambya Road Nsambya Hill, P.O. Box 7146</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticolon@insight-trials.rog</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Lira Regional Referral Hospital (Site 634-605)</name>
      <address>
        <city>Lira</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticolon@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Masaka Regional Referral Hospital (Site 634-606), MRC/UVRI and LSHTM Uganda Research Unit, Plot 6 Circle Road, PO Box 556</name>
      <address>
        <city>Masaka</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticolon@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Infirmary (Site 634-007), Queen Victoria Road</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <state>Northumbria</state>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in particiating at this site, enter site name and ACITV-3 in subject line of email and send to</last_name>
      <email>ticolon@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital (Site 634-006), Dept. of Infectious Diseases / HIV Medicine, Pond Street, Hampstead</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticolon@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Guy's and St. Thomas' NHS Foundation Trust (Site 634-011)</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and ACTIV-3 in subject line of email and send to</last_name>
      <email>ticolon@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Denmark</country>
    <country>Georgia</country>
    <country>Greece</country>
    <country>India</country>
    <country>Mozambique</country>
    <country>Nigeria</country>
    <country>Poland</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Uganda</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>https://www.cdc.gov/coronavirus/2019-nCoV/index.html</url>
    <description>CDC (Centers for Disease Control and Prevention): Coronavirus (COVID-19) website</description>
  </link>
  <link>
    <url>https://www.niaid.nih.gov/clinical-trials/participant-guide</url>
    <description>A Participant's Guide to Clinical Trials (NIAID)</description>
  </link>
  <link>
    <url>https://www.niaid.nih.gov/clinical-trials/find-a-clinical-trial</url>
    <description>Find a Clinical Trial (NIAID)</description>
  </link>
  <link>
    <url>https://www.niaid.nih.gov/clinical-trials</url>
    <description>Clinical Trials at NIAID</description>
  </link>
  <link>
    <url>https://www.niaid.nih.gov/</url>
    <description>National Institute for Allergy and Infectious Diseases (NIAID)</description>
  </link>
  <link>
    <url>https://www.covid19treatmentguidelines.nih.gov/</url>
    <description>NIH COVID-19 treatment guidelines</description>
  </link>
  <link>
    <url>https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/patient-management</url>
    <description>WHO COVID-19 treatment guidelines</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 3, 2020</study_first_submitted>
  <study_first_submitted_qc>August 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2020</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>COVID 19</keyword>
  <keyword>Coronaviridae Infections</keyword>
  <keyword>Coronavirus Infections</keyword>
  <keyword>RNA Virus Infections</keyword>
  <keyword>Virus Diseases</keyword>
  <keyword>Nidovirales Infections</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>SARS Coronavirus</keyword>
  <keyword>ACTIV-3</keyword>
  <keyword>ACTIV3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remdesivir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

